Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Change in Acquisitions & Divestments (2023 - 2025)

Compass Therapeutics' Change in Acquisitions & Divestments history spans 3 years, with the latest figure at $24.1 million for Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments fell 4.49% year-over-year to $24.1 million; the TTM value through Dec 2025 reached $101.3 million, down 24.97%, while the annual FY2025 figure was $101.3 million, 24.97% down from the prior year.
  • Change in Acquisitions & Divestments for Q4 2025 was $24.1 million at Compass Therapeutics, up from $13.9 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $59.2 million in Q1 2023 and bottomed at $13.9 million in Q3 2025.
  • The 3-year median for Change in Acquisitions & Divestments is $35.4 million (2023), against an average of $34.9 million.
  • The largest annual shift saw Change in Acquisitions & Divestments grew 0.44% in 2024 before it crashed 59.52% in 2025.
  • A 3-year view of Change in Acquisitions & Divestments shows it stood at $51.4 million in 2023, then plummeted by 50.91% to $25.2 million in 2024, then fell by 4.49% to $24.1 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Change in Acquisitions & Divestments are $24.1 million (Q4 2025), $13.9 million (Q3 2025), and $26.8 million (Q2 2025).